10 results on '"Laura Rivas"'
Search Results
2. 14 - ¿QUÉ FACTORES SE ASOCIAN AL DIAGNÓSTICO ÓPTICO DEL SISTEMA DE AYUDA AL DIAGNÓSTICO, POLYDEEP? ANÁLISIS IN VITRO
- Author
-
Pedro Dávila Piñón, Cristina Regueiro Expósito, Astrid Irene Diez Martín, Jorge Hernández Camoiras, Jesús M. Herrero Rivas, Manuel Puga Giménez de Azcárate, Laura Rivas Moral, Eloy Sánchez Hernández, Rubén Domínguez Carbajales, Florentino Fernández Riverola, Hugo López Fernández, Alba Nogueira Rodríguez, Alejandro González García, Miguel Reboiro Jato, Daniel González Peña, and Joaquín Cubiella Fernández
- Subjects
Hepatology ,Gastroenterology - Published
- 2023
3. INCIDENCIA, TASA DE DETECCIÓN DE ADENOMAS Y FACTORES DE RIESGO DE CRC SEGÚN EL GEN AFECTO EN EL SÍNDROME DE LYNCH
- Author
-
Ariadna Sánchez, Joaquin Castillo, Victorine H. Roos, Núria Dueñas, Marta Pineda, Berta Caballol, Lorena Moreno, Sabela Carballal, Lorena Rodríguez-Alonso, Teresa Ramón y Cajal, Gemma Llort, Virginia Piñol, Adrià López Fernández, Inmaculada Salces, Maria Dolores Picó, Laura Rivas, Luis Bujanda, Marta Garzón, Angeles Pizarro, Eva Martínez de Castro, Maria Jesus López-Arias, Carmen Poves, Catalina Garau, Daniel Rodríguez- Alcalde, Maite Herraiz, Cristina Alvarez-Urrutia, Andrés Dacal, Marta Carrillo-Palau, Lucia Cid, Marta Ponce, Eva Barreiro-Alonso, Esteban Saperas, Elena Aguirre, Teresa Ocaña, Liseth Rivero- Sánchez, Xavier Bessa, Joaquin Cubiella, Rodrigo Jover, Francisco Rodríguez-Moranta, Judith Balmaña, Joan Brunet, Antoni Castells, Evelien Dekker, Gabriel Capella, Leticia Moreira, Maria Pellise, and Francesc Balaguer
- Subjects
Hepatology ,Gastroenterology - Published
- 2023
4. Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome
- Author
-
Daniel Rodríguez-Alcalde, Angeles Pizarro, Maria Pellise, Cristina Romero, Berta Caballol, Lorena Moreno, Esteban Saperas, Eva Martinez de Castro, Gemma Llort, Laura Rivas, Catalina Garau, Ariadna Sánchez, Elena Aguirre, Sabela Carballal, Virginia Piñol, Eva Barreiro-Alonso, Matilde Navarro, Lorena Rodríguez-Alonso, Marta Garzon, Xavier Bessa, Teresa Ocaña, Marta Ponce, Carmen Poves, Inmaculada Salces, Gerhard Jung, Cristina Alvarez-Urrutia, Maite Herraiz, Liseth Rivero-Sánchez, Evelien Dekker, Joan Brunet, Judith Balmaña, Maribel Gonzalez-Acosta, Francesc Balaguer, Blai Morales-Romero, Luis Bujanda, Leticia Moreira, Joaquín Cubiella, Teresa Ramón y Cajal, Marta Pineda, Miquel Serra-Burriel, Victorine H. Roos, María Dolores Picó, Andres Dacal, Antoni Castells, Lucía Cid, Maria Jesus López-Arias, Rodrigo Jover, Francisco Rodríguez-Moranta, Gabriel Capellá, Marta Carrillo-Palau, Barbara A. J. Bastiaansen, Adrià López-Fernández, Gastroenterology and Hepatology, Graduate School, APH - Methodology, APH - Personalized Medicine, CCA - Imaging and biomarkers, CCA - Cancer Treatment and Quality of Life, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism
- Subjects
Adenoma ,medicine.medical_specialty ,Colorectal cancer ,Colonoscopy ,HNPCC ,Chromoendoscopy ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Interquartile range ,Internal medicine ,medicine ,Humans ,Cumulative incidence ,Colonoscopy Quality ,Colorectal Neoplasms, HNPCC, Hereditary Non-Polyposis Colorectal Cancer, Lynch syndrome, colonoscopy quality, colonoscopy, hereditary colorectal cancer ,neoplasms ,Early Detection of Cancer ,Hereditary Colorectal Cancer ,Hepatology ,medicine.diagnostic_test ,business.industry ,Incidence ,Incidence (epidemiology) ,Gastroenterology ,Hereditary Nonpolyposis Colorectal Cancer ,Odds ratio ,colonoscopy quality, colonoscopy ,medicine.disease ,Colorectal Neoplasms, Hereditary Nonpolyposis ,Lynch syndrome ,digestive system diseases ,Hereditary Non-Polyposis Colorectal Cancer ,030220 oncology & carcinogenesis ,Lynch Syndrome ,030211 gastroenterology & hepatology ,business ,Colorectal Neoplasms - Abstract
BACKGROUND & AIMS: Colonoscopy reduces colorectal cancer (CRC) incidence and mortality in Lynch syndrome (LS) carriers. However, a high incidence of postcolonoscopy CRC (PCCRC) has been reported. Colonoscopy is highly dependent on endoscopist skill and is subject to quality variability. We aimed to evaluate the impact of key colonoscopy quality indicators on adenoma detection and prevention of PCCRC in LS. METHODS: We conducted a multicenter study focused on LS carriers without previous CRC undergoing colonoscopy surveillance (n = 893). Incident colorectal neoplasia during surveillance and quality indicators of all colonoscopies were analyzed. We performed an emulated target trial comparing the results from the first and second surveillance colonoscopies to assess the effect of colonoscopy quality indicators on adenoma detection and PCCRC incidence. Risk analyses were conducted using a multivariable logistic regression model. RESULTS: The 10-year cumulative incidence of adenoma and PCCRC was 60.6% (95% CI, 55.5%-65.2%) and 7.9% (95% CI, 5.2%-10.6%), respectively. Adequate bowel preparation (odds ratio [OR], 2.07; 95% CI, 1.06-4.3), complete colonoscopies (20% vs 0%; P = .01), and panchromoendoscopy use (OR, 2.14; 95% CI, 1.15-3.95) were associated with significant improvement in adenoma detection. PCCRC risk was significantly lower when colonoscopies were performed during a time interval of less than every 3 years (OR, 0.35; 95% CI, 0.14-0.97). We observed a consistent but not significant reduction in PCCRC risk for a previous complete examination (OR, 0.16; 95% CI, 0.03-1.28), adequate bowel preparation (OR, 0.64; 95% CI, 0.17-3.24), or previous use of high-definition colonoscopy (OR, 0.37; 95% CI, 0.02-2.33). CONCLUSIONS: Complete colonoscopies with adequate bowel preparation and chromoendoscopy use are associated with improved adenoma detection, while surveillance intervals of less than 3 years are associated with a reduction of PCCRC incidence. In LS, high-quality colonoscopy surveillance is of utmost importance for CRC prevention.
- Published
- 2022
5. 598 POST-COLONOSCOPY COLORECTAL CANCER IN LYNCH SYNDROME IS ASSOCIATED WITH QUALITY ISSUES DURING SURVEILLANCE
- Author
-
Adolfo Suárez, Esteban Saperas, Daniel Rodríguez-Alcalde, Ariadna Sanchez Garcia, Lorena Moreno, Joan Brunet, Miquel Serra, Elena Aguirre, Marta Ponce, Teresa Ocaña, Marta Carrillo-Palau, Antoni Castells, Andres Dacal, Laura Rivas, Catalina Garau, Virginia Piñol, Berta Caballol, Liseth Rivero, M. J. López-Arias, Teresa Ramón y Cajal, Eva Martínez de Castro, Carmen Poves, Lorena Rodríguez-Alonso, Inmaculada Salces, Francisco Rodríguez-Moranta, Cristina de la Peña Álvarez, Lucía Cid, Maite Herraiz, Gemma Llort, Francesc Balaguer, Evelien Dekker, Gabriel Capellá, Victorine H. Roos, Adrià Lopez Fernandez, Luis Bujanda, María Dolores Picó, Marta Garzon, Leticia Moreira, Matilde Navarro, Xavier Bessa, Maria Pellise, Rodrigo Jover, J. Balmaña, Angeles Pizarro, Sabela Carballal, Joaquín Cubiella, and Marta Pineda
- Subjects
medicine.medical_specialty ,Hepatology ,medicine.diagnostic_test ,business.industry ,Colorectal cancer ,media_common.quotation_subject ,General surgery ,Gastroenterology ,Colonoscopy ,medicine.disease ,Lynch syndrome ,Medicine ,Quality (business) ,business ,media_common - Published
- 2020
6. Clinical and Pathological Characterization of Lynch-Like Syndrome
- Author
-
Teresa Ramón y Cajal, Ariadna Sánchez, Maria Pellise, Mar Giner-Calabuig, Francesc Balaguer, Maite Herraiz, Luis Bujanda, Adela Castillejo, Cristina Alenda, Leticia Moreira, María Dolores Picó, Rodrigo Jover, Lucía Cid, Adrià López-Fernández, Marta Garzon, Miren Alustiza, Marta Ponce, Antoni Castells, Cristina Alvarez-Urturi, Carmen Poves, Inmaculada Salces, Luis Hernández-Villalba, Laura Rivas, Catalina Garau, Oscar Murcia, Daniel Rodríguez-Alcalde, Carmen Yagüe, Joaquín Cubiella, José-Luis Soto, Carlos Dolz, Alexandra Gisbert-Beamud, Gemma Llort, and Marta Carrillo-Palau
- Subjects
Risk ,Oncology ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Colorectal cancer ,colon tumor, familial, genetic, polyp, risk ,Colon Tumor ,complex mixtures ,DNA Mismatch Repair ,03 medical and health sciences ,symbols.namesake ,Familial ,Polyp ,0302 clinical medicine ,Genetic ,Neoplastic Syndromes, Hereditary ,Internal medicine ,medicine ,PMS2 ,Humans ,Family history ,neoplasms ,Fisher's exact test ,Hepatology ,business.industry ,Gastroenterology ,nutritional and metabolic diseases ,Microsatellite instability ,medicine.disease ,Colorectal Neoplasms, Hereditary Nonpolyposis ,digestive system diseases ,Lynch syndrome ,MSH6 ,MSH2 ,030220 oncology & carcinogenesis ,symbols ,Female ,Microsatellite Instability ,030211 gastroenterology & hepatology ,Colorectal Neoplasms ,MutL Protein Homolog 1 ,business - Abstract
BACKGROUND & AIMS: Lynch syndrome is characterized by DNA mismatch repair (MMR) deficiency. Some patients with suspected Lynch syndrome have DNA MMR deficiencies but no detectable mutations in genes that encode MMR proteins-this is called Lynch-like syndrome (LLS). There is no consensus on management of patients with LLS. We collected data from a large series of patients with LLS to identify clinical and pathology features. METHODS: We collected data from a nationwide-registry of patients with colorectal cancer (CRC) in Spain. We identified patients whose colorectal tumors had loss of MSH2, MSH6, PMS2, or MLH1 (based on immunohistochemistry), without the mutation encoding V600E in BRAF (detected by real-time PCR), and/or no methylation at MLH1 (determined by methylation-specific multiplex ligation-dependent probe amplification), and no pathogenic mutations in MMR genes, BRAF, or EPCAM (determined by DNA sequencing). These patients were considered to have LLS. We collected data on demographic, clinical, and pathology features and family history of neoplasms. The chi(2) test was used to analyze the association between qualitative variables, followed by the Fisher exact test and the Student t test or the Mann-Whitney test for quantitative variables. RESULTS: We identified 160 patients with LLS; their mean age at diagnosis of CRC was 55 years and 66 patients were female (41%). The Amsterdam I and II criteria for Lynch syndrome were fulfilled by 11% of cases and the revised Bethesda guideline criteria by 65% of cases. Of the patients with LLS, 24% were identified in universal screening. There were no proportional differences in sex, indication for colonoscopy, immunohistochemistry, pathology findings, or personal history of CRC or other Lynch syndrome-related tumors between patients who met the Amsterdam and/or Bethesda criteria for Lynch syndrome and patients identified in universal screening for Lynch syndrome, without a family history of CRC. CONCLUSIONS: Patients with LLS have homogeneous clinical, demographic, and pathology characteristics, regardless of family history of CRC.
- Published
- 2020
7. Mo1736 - Identification of Clinical, Genetic and Endoscopic Predictors of Incident Colorectal Cancer in Lynch Syndrome
- Author
-
Elena Aguirre, Daniel Rodríguez-Alcalde, Xavier Bessa, Liseth Rivero, Lorena Rodríguez-Alonso, Gemma Llort, Carme Yagüe, Virginia Piñol, Marta Carrillo-Palau, Adolfo Suárez, Matilde Navarro, Maria Pellise, Ariadna Sánchez, Lorena Moreno, Andres Dacal, Leticia Moreira, Eva Martínez de Castro, Marta Ponce, Esteban Saperas, Angeles Pizarro, Carmen Poves, Inmaculada Salces, Teresa Ocaña, Laura Rivas, Catalina Garau, Sabela Carballal, Adrià Lopez Fernandez, Marta Garzon, Joan Brunet, Maite Herraiz, Teresa Ramón y Cajal, Cristina de la Peña Álvarez, Alexandra Gisbert-Beamud, Francesc Balaguer, Luis Bujanda, Antoni Castells, Lucía Cid, J. Balmaña, María Dolores Picó, Rodrigo Jover, Miquel Serra-Burriel, Gabriel Capellá, Francisco Rodríguez-Moranta, Joaquín Cubiella, and Marta Pineda
- Subjects
Oncology ,medicine.medical_specialty ,Hepatology ,Colorectal cancer ,business.industry ,Internal medicine ,Gastroenterology ,medicine ,Clinical genetic ,Identification (biology) ,medicine.disease ,business ,Lynch syndrome - Published
- 2018
8. 1071 - Clinical and Molecular Characterization of Lynch-Like Syndrome
- Author
-
Esteban Saperas, Xavier Bessa, Carme Yagüe, Daniel Rodríguez-Alcalde, Andres Dacal, Virginia Piñol, Joaquín Cubiella, Antoni Castells, Leticia Moreira, María Dolores Picó, Oscar Murcia, Adrià Lopez Fernandez, Miren Alustiza, Adela Castillejo, Marta Carrillo-Palau, Eva Martínez de Castro, Teresa Ramón y Cajal, Cristina de la Peña Álvarez, Ariadna Sánchez, Marta Garzon, Elena Aguirre, Ana Beatriz Sánchez, Lucía Cid, Marta Ponce, Alexandra Gisbert-Beamud, Francesc Balaguer, Maria Pellise, Mar Giner-Calabuig, Luis Bujanda, Angeles Pizarro, Rodrigo Jover, Maite Herraiz, Laura Rivas, Catalina Garau, José Luis Soto, Carmen Poves, Inmaculada Salces, J. Balmaña, and Gemma Llort
- Subjects
Hepatology ,Gastroenterology ,Computational biology ,Biology ,Characterization (materials science) - Published
- 2018
9. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis
- Author
-
Josep Miñana, Núria Ramos, Rosa Saenz, Annalisa Berzigotti, Javier Martínez, Alba Ardevol, Pau Bellot, Rosa Maria Morillas, Joan Genescà, José Mera Calviño, Càndid Villanueva, Juan Turnes, Jose Luis Calleja, Ramon Planas, Angela Puente, Salvador Augustin, Josep Maria Reñe, José Ríos, Agustín Albillos, Juan Buenestado, José Castellote, Joan Albert Arnaiz, Laura Millán, Judit Pich, Fanny Turon, Carles Aracil, Helena Beleta, José Such, Laura Rivas Moral, Carmen A. Navacués, Alba Cachero, A. Girbau, Oana Pavel, Jaime Bosch, Juan Carlos García-Pagán, Ferran Torres, Manuel J. Rodriguez, Dalia Morales Arraez, Juan G. Abraldes, Mercedes Vergara, Joaquín de la Peña, Goretti Hernández Mesa, Enric Reverter, Edilmar Alvarado, Manuel Hernández-Guerra, Susana Seijo, and Elba Llop
- Subjects
Liver Cirrhosis ,Male ,medicine.medical_specialty ,Simvastatin ,Cirrhosis ,Time Factors ,Portal venous pressure ,Adrenergic beta-Antagonists ,Kaplan-Meier Estimate ,Placebo ,Esophageal and Gastric Varices ,Gastroenterology ,Rhabdomyolysis ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Model for End-Stage Liver Disease ,Randomized controlled trial ,Double-Blind Method ,law ,Interquartile range ,Recurrence ,Risk Factors ,Internal medicine ,medicine ,Humans ,Ligation ,Aged ,Proportional Hazards Models ,Hepatology ,business.industry ,Hazard ratio ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Surgery ,Treatment Outcome ,Spain ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Female ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,business ,Gastrointestinal Hemorrhage ,medicine.drug - Abstract
Background & Aims The combination of β-blockers and band ligation is the standard approach to prevent variceal rebleeding, but bleeding recurs and mortality is high. The lipid-lowering drug simvastatin decreases portal pressure, improves hepatocellular function, and might reduce liver fibrosis. We assessed whether adding simvastatin to standard therapy could reduce rebleeding and death after variceal bleeding in patients with cirrhosis. Methods We performed a multicenter, double-blind, parallel trial of 158 patients with cirrhosis receiving standard prophylaxis to prevent rebleeding (a β-blocker and band ligation) in Spain from October 2010 through October 2013. Within 10 days of bleeding, subjects were randomly assigned, but stratified by Child-Pugh class of A or B vs C, to groups given simvastatin (20 mg/d the first 15 days, 40 mg/d thereafter; n = 69) or placebo (n = 78). Patients were followed for as long as 24 months. The primary end point was a composite of rebleeding and death, and main secondary end points were the individual components of the composite (death and rebleeding). Results The primary end point was met by 30 of 78 patients in the placebo group and 22 of 69 in the simvastatin group ( P = .423). Seventeen patients in the placebo group died (22%) vs 6 patients in the simvastatin group (9%) (hazard ratio for adding simvastatin to therapy = 0.39; 95% confidence interval: 0.15–0.99; P = .030). Simvastatin did not increase survival of patients with Child-Pugh class C cirrhosis. Rebleeding occurred in 28% of patients in the placebo group and 25% in the simvastatin group ( P = .583). Serious adverse events occurred in 53% of patients in the placebo group and 49% in the simvastatin group ( P = .752); the percentages of serious adverse events related to therapy were 11% in the placebo group vs 8% in the in the simvastatin group ( P = .599). Two patients in the simvastatin group, each with advanced liver disease, developed rhabdomyolysis. Conclusions In a randomized controlled trial, addition of simvastatin to standard therapy did not reduce rebleeding, but was associated with a survival benefit for patients with Child-Pugh class A or B cirrhosis. Survival was not the primary end point of the study, so these results require validation. The incidence of rhabdomyolysis in patients receiving 40 mg/d simvastatin was higher than expected. European Clinical Trial Database ID: EUDRACT 2009-016500-24; ClinicalTrials.gov ID: NCT01095185.
- Published
- 2015
10. Stauffer’s Syndrome Variant as an Unusual Case of Painless Jaundice
- Author
-
Enrique Gonzalez-Ballina, Laura Rivas-Moral, and Manuel Puga
- Subjects
Male ,Radiography, Abdominal ,medicine.medical_specialty ,S syndrome ,Unusual case ,Hepatology ,business.industry ,Gastroenterology ,Jaundice ,Kidney Neoplasms ,Tomography x ray computed ,Humans ,Painless jaundice ,Medicine ,Radiology ,medicine.symptom ,Tomography, X-Ray Computed ,business ,Carcinoma, Renal Cell ,Aged - Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.